The Survival of Motor Neuron (SMN) Protein Interacts with the Mrna-Binding Protein Hud and Regulates Localization of Poly(A) Mrna in Primary Motor Neuron Axons
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
RNA-Binding Protein Network Alteration Causes Aberrant Axon
bioRxiv preprint doi: https://doi.org/10.1101/2020.08.26.268631; this version posted August 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 RNA-binding protein network alteration causes aberrant axon 2 branching and growth phenotypes in FUS ALS mutant motoneurons 3 4 Maria Giovanna Garone1, Nicol Birsa2,3, Maria Rosito4, Federico Salaris1,4, Michela Mochi1, Valeria 5 de Turris4, Remya R. Nair5, Thomas J. Cunningham5, Elizabeth M. C. Fisher2, Pietro Fratta2 and 6 Alessandro Rosa1,4,6,* 7 8 1. Department of Biology and Biotechnology Charles Darwin, Sapienza University of Rome, P.le 9 A. Moro 5, 00185 Rome, Italy 10 2. UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, 11 UK 12 3. UK Dementia Research Institute, University College London, London, WC1E 6BT, UK 13 4. Center for Life Nano Science, Istituto Italiano di Tecnologia, Viale Regina Elena 291, 00161 14 Rome, Italy 15 5. MRC Harwell Institute, Oxfordshire, OX11 0RD, UK 16 6. Laboratory Affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of 17 Biology and Biotechnology Charles Darwin, Sapienza University of Rome, Viale Regina Elena 18 291, 00161 Rome, Italy 19 20 * Corresponding author: [email protected]; Tel: +39-0649255218 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.26.268631; this version posted August 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. -
Emerging Roles for 3 Utrs in Neurons
International Journal of Molecular Sciences Review 0 Emerging Roles for 3 UTRs in Neurons Bongmin Bae and Pedro Miura * Department of Biology, University of Nevada, Reno, NV 89557, USA; [email protected] * Correspondence: [email protected] Received: 8 April 2020; Accepted: 9 May 2020; Published: 12 May 2020 Abstract: The 30 untranslated regions (30 UTRs) of mRNAs serve as hubs for post-transcriptional control as the targets of microRNAs (miRNAs) and RNA-binding proteins (RBPs). Sequences in 30 UTRs confer alterations in mRNA stability, direct mRNA localization to subcellular regions, and impart translational control. Thousands of mRNAs are localized to subcellular compartments in neurons—including axons, dendrites, and synapses—where they are thought to undergo local translation. Despite an established role for 30 UTR sequences in imparting mRNA localization in neurons, the specific RNA sequences and structural features at play remain poorly understood. The nervous system selectively expresses longer 30 UTR isoforms via alternative polyadenylation (APA). The regulation of APA in neurons and the neuronal functions of longer 30 UTR mRNA isoforms are starting to be uncovered. Surprising roles for 30 UTRs are emerging beyond the regulation of protein synthesis and include roles as RBP delivery scaffolds and regulators of alternative splicing. Evidence is also emerging that 30 UTRs can be cleaved, leading to stable, isolated 30 UTR fragments which are of unknown function. Mutations in 30 UTRs are implicated in several neurological disorders—more studies are needed to uncover how these mutations impact gene regulation and what is their relationship to disease severity. Keywords: 30 UTR; alternative polyadenylation; local translation; RNA-binding protein; RNA-sequencing; post-transcriptional regulation 1. -
Characterization of E Coli Hfq Structure and Its Rna Binding Properties
CHARACTERIZATION OF E COLI HFQ STRUCTURE AND ITS RNA BINDING PROPERTIES A thesis Presented to The Academic Faculty By Xueguang Sun In partial Fulfillment Of the Requirement for the Degree Doctor of Philosophy in the School of Biology Georgia Institute of Technology May 2006 Copyright Ó 2006 by Xueguang Sun CHARACTERIZATION OF E COLI HFQ STRUCTURE AND ITS RNA BINDING PROPERTIES Approved by : Roger M. Wartell, Chair Stephen C. Harvey School of Biology School of Biology Georgia Institute of Technology Georgia Institute of Technology Yury O. Chernoff Stephen Spiro School of Biology School of Biology Georgia Institute of Technology Georgia Institute of Technology Loren D Willimas School of Chemistry and Biochmestry Georgia Institute of Technology Date Approved: November 29 2005 To my family, for their constant love and support. iii ACKNOWLEDGEMENTS There are many people I would like to thank and acknowledge for their support and help during my five-year Ph.D. study. First and foremost, I would like to thank my advisor, Dr Roger Wartell, for his guidance and assistance throughout this chapter of my career. His constantly open door, scientific insight and perspective, and technical guidance have been integral to furthering my scientific education. He also provided knowledgeable recommendations and multi-faceted support in my personal life and bridged me to a culture which I have never experienced. Without him, it would be impossible to accomplish this thesis work. I would like to acknowledge Dr. Stephen Harvey, Dr. Yury Chernoff, Dr. Stephen Spiro and Dr. Loren Williams for being on my thesis committee and helpful discussion in structural modeling. -
New Insights Into Functional Roles of the Polypyrimidine Tract-Binding Protein
Int. J. Mol. Sci. 2013, 14, 22906-22932; doi:10.3390/ijms141122906 OPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 www.mdpi.com/journal/ijms Review New Insights into Functional Roles of the Polypyrimidine Tract-Binding Protein Maria Grazia Romanelli *, Erica Diani and Patricia Marie-Jeanne Lievens Department of Life and Reproduction Sciences, Section of Biology and Genetics, University of Verona, Strada Le Grazie 8, 37134 Verona, Italy; E-Mails: [email protected] (E.D.); [email protected] (P.M.-J.L.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +39-045-8027182; Fax: +39-045-8027180. Received: 22 September 2013; in revised form: 13 November 2013 / Accepted: 13 November 2013 / Published: 20 November 2013 Abstract: Polypyrimidine Tract Binding Protein (PTB) is an intensely studied RNA binding protein involved in several post-transcriptional regulatory events of gene expression. Initially described as a pre-mRNA splicing regulator, PTB is now widely accepted as a multifunctional protein shuttling between nucleus and cytoplasm. Accordingly, PTB can interact with selected RNA targets, structural elements and proteins. There is increasing evidence that PTB and its paralog PTBP2 play a major role as repressors of alternatively spliced exons, whose transcription is tissue-regulated. In addition to alternative splicing, PTB is involved in almost all steps of mRNA metabolism, including polyadenylation, mRNA stability and initiation of protein translation. Furthermore, it is well established that PTB recruitment in internal ribosome entry site (IRES) activates the translation of picornaviral and cellular proteins. Detailed studies of the structural properties of PTB have contributed to our understanding of the mechanism of RNA binding by RNA Recognition Motif (RRM) domains. -
Decreased Function of Survival Motor Neuron Protein Impairs Endocytic
Decreased function of survival motor neuron protein PNAS PLUS impairs endocytic pathways Maria Dimitriadia,b, Aaron Derdowskic,1, Geetika Kallooa,1, Melissa S. Maginnisc,d, Patrick O’Herna, Bryn Bliskaa, Altar Sorkaça, Ken C. Q. Nguyene, Steven J. Cooke, George Poulogiannisf, Walter J. Atwoodc, David H. Halle, and Anne C. Harta,2 aDepartment of Neuroscience, Brown University, Providence, RI 02912; bDepartment of Biological and Environmental Sciences, University of Hertfordshire, Hatfield AL10 9AB, United Kingdom; cDepartment of Molecular Biology, Cell Biology, and Biochemistry, Brown University, Providence, RI 02912; dDepartment of Molecular and Biomedical Sciences, University of Maine, Orono, ME 04469; eDominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY 10461; and fChester Beatty Labs, The Institute of Cancer Research, London SW3 6JB, United Kingdom Edited by H. Robert Horvitz, Howard Hughes Medical Institute, Cambridge, MA, and approved June 2, 2016 (received for review January 23, 2016) Spinal muscular atrophy (SMA) is caused by depletion of the ubiqui- pathways most sensitive to decreased SMN is essential to un- tously expressed survival motor neuron (SMN) protein, with 1 in 40 derstand how SMN depletion causes neuronal dysfunction/death Caucasians being heterozygous for a disease allele. SMN is critical for in SMA and to accelerate therapy development. the assembly of numerous ribonucleoprotein complexes, yet it is still One of the early events in SMA pathogenesis is the loss of unclear how reduced SMN levels affect motor neuron function. Here, neuromuscular junction (NMJ) function, evidenced by muscle we examined the impact of SMN depletion in Caenorhabditis elegans denervation, neurofilament accumulation, and delayed neuro- and found that decreased function of the SMN ortholog SMN-1 per- muscular maturation (25–27). -
Comparative Interactomics Analysis of Different ALS-Associated Proteins
Acta Neuropathol (2016) 132:175–196 DOI 10.1007/s00401-016-1575-8 ORIGINAL PAPER Comparative interactomics analysis of different ALS‑associated proteins identifies converging molecular pathways Anna M. Blokhuis1 · Max Koppers1,2 · Ewout J. N. Groen1,2,9 · Dianne M. A. van den Heuvel1 · Stefano Dini Modigliani4 · Jasper J. Anink5,6 · Katsumi Fumoto1,10 · Femke van Diggelen1 · Anne Snelting1 · Peter Sodaar2 · Bert M. Verheijen1,2 · Jeroen A. A. Demmers7 · Jan H. Veldink2 · Eleonora Aronica5,6 · Irene Bozzoni3 · Jeroen den Hertog8 · Leonard H. van den Berg2 · R. Jeroen Pasterkamp1 Received: 22 January 2016 / Revised: 14 April 2016 / Accepted: 15 April 2016 / Published online: 10 May 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com Abstract Amyotrophic lateral sclerosis (ALS) is a dev- OPTN and UBQLN2, in which mutations caused loss or astating neurological disease with no effective treatment gain of protein interactions. Several of the identified inter- available. An increasing number of genetic causes of ALS actomes showed a high degree of overlap: shared binding are being identified, but how these genetic defects lead to partners of ATXN2, FUS and TDP-43 had roles in RNA motor neuron degeneration and to which extent they affect metabolism; OPTN- and UBQLN2-interacting proteins common cellular pathways remains incompletely under- were related to protein degradation and protein transport, stood. To address these questions, we performed an inter- and C9orf72 interactors function in mitochondria. To con- actomic analysis to identify binding partners of wild-type firm that this overlap is important for ALS pathogenesis, (WT) and ALS-associated mutant versions of ATXN2, we studied fragile X mental retardation protein (FMRP), C9orf72, FUS, OPTN, TDP-43 and UBQLN2 in neuronal one of the common interactors of ATXN2, FUS and TDP- cells. -
Dynamics of Survival of Motor Neuron (SMN) Protein Interaction with the Mrnabinding Protein IMP1 Facilitates Its Trafficking
Dynamics of Survival of Motor Neuron (SMN) Protein Interaction with the mRNA-Binding Protein IMP1 Facilitates Its Trafficking into Motor Neuron Axons Claudia Fallini,1,2 Jeremy P. Rouanet,1* Paul G. Donlin-Asp,1* Peng Guo,1,3 Honglai Zhang,3 Robert H. Singer,3 Wilfried Rossoll,1 Gary J. Bassell1,4 1 Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia 30322 2 Department of Neurology, UMASS Medical School, Worcester, Massachusetts 01605 3 Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, New York 10461 4 Department of Neurology and Center for Neurodegenerative Diseases, Emory University School of Medicine, Atlanta, Georgia 30322 Received 13 May 2013; revised 24 June 2013; accepted 11 July 2013 ABSTRACT: Spinal muscular atrophy (SMA) is a tive imaging techniques in primary motor neurons, we lethal neurodegenerative disease specifically affecting spi- show that IMP1 associates with SMN in individual nal motor neurons. SMA is caused by the homozygous granules that are actively transported in motor neuron deletion or mutation of the survival of motor neuron 1 axons. Furthermore, we demonstrate that IMP1 axo- (SMN1) gene. The SMN protein plays an essential role in nal localization depends on SMN levels, and that SMN the assembly of spliceosomal ribonucleoproteins. How- deficiency in SMA motor neurons leads to a dramatic ever, it is still unclear how low levels of the ubiquitously reduction of IMP1 protein levels. In contrast, no dif- expressed SMN protein lead to the selective degeneration ference in IMP1 protein levels was detected in whole of motor neurons. An additional role for SMN in the reg- brain lysates from SMA mice, further suggesting neu- ulation of the axonal transport of mRNA-binding proteins ron specific roles of SMN in IMP1 expression and (mRBPs) and their target mRNAs has been proposed. -
This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: • This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. • A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. • This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. • The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. • When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Expression and subcellular localisation of poly(A)-binding proteins Hannah Burgess PhD The University of Edinburgh 2010 Abstract Poly(A)-binding proteins (PABPs) are important regulators of mRNA translation and stability. In mammals four cytoplasmic PABPs with a similar domain structure have been described - PABP1, tPABP, PABP4 and ePABP. The vast majority of research on PABP mechanism, function and sub-cellular localisation is however limited to PABP1 and little published work has explored the expression of PABP proteins. Here, I examine the tissue distribution of PABP1 and PABP4 in mouse and show that both proteins differ markedly in their expression at both the tissue and cellular level, contradicting the widespread perception that PABP1 is ubiquitously expressed. PABP4 is shown to be widely expressed though with an expression pattern distinct from PABP1, and thus may have a biological function in many tissues. -
Investigation of RNA Binding Proteins Regulated by Mtor
Investigation of RNA binding proteins regulated by mTOR Thesis submitted to the University of Leicester for the degree of Doctor of Philosophy Katherine Morris BSc (University of Leicester) March 2017 1 Investigation of RNA binding proteins regulated by mTOR Katherine Morris, MRC Toxicology Unit, University of Leicester, Leicester, LE1 9HN The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase which plays a key role in the transduction of cellular energy signals, in order to coordinate and regulate a wide number of processes including cell growth and proliferation via control of protein synthesis and protein degradation. For a number of human diseases where mTOR signalling is dysregulated, including cancer, the clinical relevance of mTOR inhibitors is clear. However, understanding of the mechanisms by which mTOR controls gene expression is incomplete, with implications for adverse toxicological effects of mTOR inhibitors on clinical outcomes. mTOR has been shown to regulate 5’ TOP mRNA expression, though the exact mechanism remains unclear. It has been postulated that this may involve an intermediary factor such as an RNA binding protein, which acts downstream of mTOR signalling to bind and regulate translation or stability of specific messages. This thesis aimed to address this question through the use of whole cell RNA binding protein capture using oligo‐d(T) affinity isolation and subsequent proteomic analysis, and identify RNA binding proteins with differential binding activity following mTOR inhibition. Following validation of 4 identified mTOR‐dependent RNA binding proteins, characterisation of their specific functions with respect to growth and survival was conducted through depletion studies, identifying a promising candidate for further work; LARP1. -
Anti-ELAVL4 / Hud Antibody (ARG42690)
Product datasheet [email protected] ARG42690 Package: 50 μg anti-ELAVL4 / HuD antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ELAVL4 / HuD Tested Reactivity Hu, Ms, Rat Predict Reactivity Bov, Mk, Rb Tested Application IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name ELAVL4 / HuD Antigen Species Human Immunogen Synthetic peptide corresponding to aa. 8-45 of Human ELAVL4 / HuD. (MEPQVSNGPTSNTSNGPSSNNRNCPSPMQTGATTDDSK) Conjugation Un-conjugated Alternate Names HUD; HuD; Hu-antigen D; Paraneoplastic encephalomyelitis antigen HuD; PNEM; ELAV-like protein 4 Application Instructions Application table Application Dilution IHC-P 1:200 - 1:1000 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 42 kDa Observed Size ~ 45 kDa Properties Form Liquid Purification Affinity purification with immunogen. Buffer 0.2% Na2HPO4, 0.9% NaCl, 0.05% Sodium azide and 5% BSA. Preservative 0.05% Sodium azide Stabilizer 5% BSA Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated www.arigobio.com 1/4 freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ELAVL4 Gene Full Name ELAV like neuron-specific RNA binding protein 4 Function RNA-binding protein that is involved in the post-transcriptional regulation of mRNAs (PubMed:7898713, PubMed:10710437, PubMed:12034726, PubMed:12468554, PubMed:17035636, PubMed:17234598). -
The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement
International Journal of Molecular Sciences Review The Ubiquitin Proteasome System in Neuromuscular Disorders: Moving Beyond Movement 1, , 2, 3,4 Sara Bachiller * y , Isabel M. Alonso-Bellido y , Luis Miguel Real , Eva María Pérez-Villegas 5 , José Luis Venero 2 , Tomas Deierborg 1 , José Ángel Armengol 5 and Rocío Ruiz 2 1 Experimental Neuroinflammation Laboratory, Department of Experimental Medical Science, Lund University, Sölvegatan 19, 221 84 Lund, Sweden; [email protected] 2 Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad de Sevilla/Instituto de Biomedicina de Sevilla-Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, 41012 Sevilla, Spain; [email protected] (I.M.A.-B.); [email protected] (J.L.V.); [email protected] (R.R.) 3 Unidad Clínica de Enfermedades Infecciosas, Hospital Universitario de Valme, 41014 Sevilla, Spain; [email protected] 4 Departamento de Especialidades Quirúrgicas, Bioquímica e Inmunología, Facultad de Medicina, 29071 Universidad de Málaga, Spain 5 Departamento de Fisiología, Anatomía y Biología Celular, Universidad Pablo de Olavide, 41013 Sevilla, Spain; [email protected] (E.M.P.-V.); [email protected] (J.Á.A.) * Correspondence: [email protected] These authors contributed equally to the work. y Received: 14 July 2020; Accepted: 31 August 2020; Published: 3 September 2020 Abstract: Neuromuscular disorders (NMDs) affect 1 in 3000 people worldwide. There are more than 150 different types of NMDs, where the common feature is the loss of muscle strength. These disorders are classified according to their neuroanatomical location, as motor neuron diseases, peripheral nerve diseases, neuromuscular junction diseases, and muscle diseases. Over the years, numerous studies have pointed to protein homeostasis as a crucial factor in the development of these fatal diseases. -
Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021
Genetic Testing Policy Number: PG0041 ADVANTAGE | ELITE | HMO Last Review: 04/11/2021 INDIVIDUAL MARKETPLACE | PROMEDICA MEDICARE PLAN | PPO GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual policyholder terms, conditions, exclusions and limitations contract. It does not constitute a contract or guarantee regarding coverage or reimbursement/payment. Paramount applies coding edits to all medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. This medical policy is solely for guiding medical necessity and explaining correct procedure reporting used to assist in making coverage decisions and administering benefits. SCOPE X Professional X Facility DESCRIPTION A genetic test is the analysis of human DNA, RNA, chromosomes, proteins, or certain metabolites in order to detect alterations related to a heritable or acquired disorder. This can be accomplished by directly examining the DNA or RNA that makes up a gene (direct testing), looking at markers co-inherited with a disease-causing gene (linkage testing), assaying certain metabolites (biochemical testing), or examining the chromosomes (cytogenetic testing). Clinical genetic tests are those in which specimens are examined and results reported to the provider or patient for the purpose of diagnosis, prevention or treatment in the care of individual patients. Genetic testing is performed for a variety of intended uses: Diagnostic testing (to diagnose disease) Predictive